

REMARKS

Claims 1-25 are currently pending. Applicants note that all claims either amended or added in the pending Response After Final Office Action, filed September 1, 2004, except those amended herein (claims 1 and 9), are now marked as previously presented (claims 15, 24 and 25) because they were first presented in the Response After Final Office Action, although those amendments have not yet been entered. Claims 1 and 9 have been amended to more clearly define the invention. Only the newly amended matter is shown in marked-up format.

New claims 26-29 have been added to more particularly point out the subject matter of the invention. Applicants note that the cell line from which the immunoglobulin specific to B7-2 of new claims 28-29 is derived was deposited with the American Type Culture Collection during prosecution of U.S. Patent Application Serial No. 09/249,011, under Accession No. CRL-12524. A courtesy copy of the original Deposit Declaration is enclosed with this paper. All of the new and amended claims find support in the specification as filed, *see, e.g.*, page 2, line 7, to page 4, line 15; and page 42, line 8, to page 43, line 6. None of the amendments or new claims add new matter.

Applicants note that the new language of claims 1 and 9 was copied directly from an allowed antibody claim in U.S. Patent Application No. 09/249,011, and that new claims 26-29 were added to correspond to additional allowed antibody claims in the '011 application. Applicants thank the Examiner for speaking with the undersigned representative on January 12, 2003, and suggesting this amendment as a way to obviate the remaining rejections.

Applicants believe that these additional amendments, in view of the beneficial conversation with the Examiner, overcome any remaining rejections, including written description, enablement, definiteness, and prior art. Applicants maintain all of the arguments and amendments made in the Response filed September 1, 2004. Should the Examiner have any additional concerns, Applicants invite him to call the undersigned at 202-408-4086. Applicants request early examination and allowance of the application and amended claims.

CONCLUSION

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 31, 2005

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796